Biofrontera- Warrants (27/10/2026) Overview
Valuation check: BFRIW's ROE is -106.87%, below the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow-106.87%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Biofrontera- Warrants (27/10/2026) posts a ROE of -106.87%. That is below the Healthcare sector average of 21.28%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 21.28% is typical. Biofrontera- Warrants (27/10/2026)'s -106.87% is lower that level. That is roughly 602.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Biofrontera- Warrants (27/10/2026)'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -106.87%; use YoY and peer views to separate noise from signal.
Context for BFRIW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.28%), and (3) consistency with growth and profitability. This page covers the first two; Biofrontera- Warrants (27/10/2026)'s other metric pages and overview cover the third.
Judging Biofrontera- Warrants (27/10/2026) against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -106.87% here, then scan peer and history charts to see if the gap is persistent.
